Literature DB >> 27200555

Health Utility in Patients Following Cardiovascular Events.

R D Pockett1, P McEwan2, C Beckham3, S Shutler4, S Martin5, Z Yousef6, A Bakhai7.   

Abstract

Entities:  

Year:  2014        PMID： 27200555     DOI： 10.1016/j.jval.2014.08.598

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  3 in total

1.  Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Authors:  Kevin Bowrin; Jean-Baptiste Briere; Pierre Levy; Aurélie Millier; Jean Tardu; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2020-06-25

2.  Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

Authors:  Carlos Escobar Cervantes; Julio Martí-Almor; Alejandro Isidoro Pérez Cabeza; Kevin Bowrin; Aleix Llorac Moix; Mar Genís Gironès; David Gasche; Aurélie Millier; Jean Tardu; Mondher Toumi; Jean-Baptiste Briere
Journal:  PLoS One       Date:  2022-04-20       Impact factor: 3.240

3.  Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.

Authors:  Kevin Bowrin; Jean-Baptiste Briere; Laurent Fauchier; Craig Coleman; Aurélie Millier; Mondher Toumi; Emilie Clay; Pierre Levy
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.